William Blair Issues Pessimistic Outlook for KROS Earnings

Key Points

• William Blair has revised its Q3 2025 EPS forecast for Keros Therapeutics from ($0.83) to ($1.03), while also predicting lower earnings for subsequent quarters and years.
• The company reported a quarterly EPS of ($0.76), beating expectations, but revenue significantly underperformed at $0.02 million against an estimated $3.83 million.
• Analysts have downgraded Keros Therapeutics' stock ratings, with price targets decreasing significantly from previous forecasts, reflecting a more cautious outlook on the company’s performance.

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Stock analysts at William Blair cut their Q3 2025 EPS estimates for Keros Therapeutics in a research note issued to investors on Wednesday, August 6th. William Blair analyst M. Phipps now forecasts that the company will earn ($1.03) per share for the quarter, down from their previous forecast of ($0.83). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics' Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at $0.82 EPS, Q1 2026 earnings at ($1.17) EPS, Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($1.20) EPS, Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($4.77) EPS, FY2027 earnings at ($4.48) EPS and FY2028 earnings at ($3.95) EPS.

Other equities analysts have also issued research reports about the stock. Bank of America lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. Scotiabank lowered their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. HC Wainwright lowered their price target on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research report on Friday. Finally, Wedbush restated a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Friday, May 30th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Stock Up 2.7%

Shares of NASDAQ:KROS traded up $0.36 on Monday, reaching $13.71. 305,989 shares of the company's stock were exchanged, compared to its average volume of 999,934. The firm has a market capitalization of $556.90 million, a price-to-earnings ratio of 44.23, a PEG ratio of 1.80 and a beta of 1.33. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The business's 50-day moving average is $14.00 and its two-hundred day moving average is $12.81.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.38. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The firm's quarterly revenue was up 49002.7% on a year-over-year basis. During the same period in the prior year, the company posted ($1.25) earnings per share.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd lifted its holdings in Keros Therapeutics by 12.5% in the 2nd quarter. XTX Topco Ltd now owns 54,145 shares of the company's stock valued at $723,000 after acquiring an additional 6,024 shares during the last quarter. Rhumbline Advisers lifted its holdings in Keros Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company's stock valued at $692,000 after acquiring an additional 7,146 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Keros Therapeutics by 245.5% in the 2nd quarter. Franklin Resources Inc. now owns 132,301 shares of the company's stock valued at $1,766,000 after acquiring an additional 94,006 shares during the last quarter. Creative Planning lifted its holdings in Keros Therapeutics by 40.2% in the 2nd quarter. Creative Planning now owns 24,226 shares of the company's stock valued at $323,000 after acquiring an additional 6,948 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in Keros Therapeutics by 29.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock valued at $110,000 after acquiring an additional 1,892 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.